Heron Therapeutics' (HRTX) Price Target Raised to $54 at BofA/Merrill Lynch
Tweet
Share
E-mailGet Alerts HRTX Hot Sheet
Price: $0.43 -4.44%
Rating Summary:
18 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 19 | New: 38
Rating Summary:
18 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 19 | New: 38
Join SI Premium – FREE
BofA/Merrill Lynch maintained a Buy rating on Heron Therapeutics (NASDAQ: HRTX) and raised its price target to $54.00 (from $46.00). The change follows positive phase 2 top-line results from HTX-011.
For an analyst ratings summary and ratings history on Heron Therapeutics click here. For more ratings news on Heron Therapeutics click here.
Shares of Heron Therapeutics closed at $33.56 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ionis Pharmaceuticals (IONS) PT Lowered to $90 at BofA Securities
- Nlight (LASR) PT Raised to $90 at Needham after DoW contract
- ENN Energy Holdings Limited (2688:HK) (XNGSY) PT Lowered to HK$65 at HSBC
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
